key: cord-0839412-7138xv3l authors: Andina‐Martinez, David; Alonso‐Cadenas, Jose A.; Cobos‐Carrascosa, Elena; Bodegas, Inmaculada; Oltra‐Benavent, Manuel; Plazaola, Ane; Epalza, Cristina; Jimenez‐García, Raquel; Moraleda, Cinta; Tagarro, Alfredo title: SARS‐CoV‐2 acute bronchiolitis in hospitalized children: Neither frequent nor more severe date: 2021-10-25 journal: Pediatr Pulmonol DOI: 10.1002/ppul.25731 sha: 162df1c2ba348e69ea8c6e2fca59d332bc572750 doc_id: 839412 cord_uid: 7138xv3l INTRODUCTION: Endemic coronaviruses have been found in acute bronchiolitis, mainly as a coinfecting virus. Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has been responsible for respiratory illness in hospitalized children. The characteristics of patients with bronchiolitis have not been extensively described. METHODS: Cross‐sectional study of patients with bronchiolitis and SARS‐CoV‐2 infection enrolled in a prospective multicenter cohort of children hospitalized with COVID‐19 in Spain from March 1, 2020 to February 28, 2021. RESULTS: Twelve of 666 children infected with SARS‐CoV‐2 who required hospital admission met the diagnostic criteria for bronchiolitis (1.8%). Median age was 1.9 months (range: 0.4–10.1). Six cases had household contact with a confirmed or probable COVID‐19 case. Main complaints were cough (11 patients), rhinorrhea (10), difficulty breathing (8), and fever (8). Eleven cases were classified as mild or moderate and one as severe. Laboratory tests performed in seven patients did not evidence anemia, lymphopenia, or high C‐reactive protein levels. Chest X‐rays were performed in six children, and one case showed remarkable findings. Coinfection with metapneumovirus was detected in the patient with the most severe course; Bordetella pertussis was detected in another patient. Seven patients required oxygen therapy. Albuterol was administered in four patients. One patient was admitted to the pediatric intensive care unit. Median length of admission was 4 days (range: 3–14). No patient died or showed any sequelae at discharge. Two patients developed recurrent bronchospasms. CONCLUSION: SARS‐CoV‐2 infection does not seem to be a main trigger of severe bronchiolitis, and children with this condition should be managed according to clinical practice guidelines. The coronaviruses 229E and OC43, discovered in the 1960s, and NL63 and HKU1, identified in the 2000s, have been described as the causative pathogen in upper respiratory tract infections, asthma, bronchiolitis, pneumonia, and croup, with more severe disease occurring in infants, the elderly, and immunocompromised individuals. Among hospitalized children, clinical manifestations and severity of illness were similar across the four human coronavirus (HCoV) types, and children under 2 years of age and those with chronic complex conditions were found to be at risk of increased disease severity. 1 As with endemic coronaviruses, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the disease that causes coronavirus disease 2019 , is responsible for respiratory illness in hospitalized children. 2 Pneumonia has been the main clinical diagnosis in pediatric patients with Acute bronchiolitis (AB) is the most common cause of hospitalization among infants during the first 12 months of life. 4 In infants seeking care for AB, respiratory syncytial virus (RSV) is the most common infection. 5 Previously, human coronavirus (HCoVs) were an infrequent cause of single-infection AB. 5, 6 Although endemic coronavirus was found in 12% of children hospitalized with AB during the pre-COVID-19 era, it has been reported that 85% of endemic coronavirus AB cases had a coinfecting virus, mainly RSV. Coinfection has not been associated with increased disease severity. 7 To the best of our knowledge, there are scarce reports of infants with AB in whom SARS-CoV-2 was the only infection detected. 8 SARS-CoV-2 infection has been found to have a low impact on pediatric acute respiratory disease hospitalizations, and AB seems to be an infrequent diagnosis. 9 Several mechanisms have been proposed to explain the varying severity of SARS-CoV-2 infection between adult and pediatric patients. 10 We analyzed data from a prospective multicenter cohort of children hospitalized with COVID-19 in Spain, one of the countries with the highest prevalence of COVID-19 in Europe, 11, 12 to describe the characteristics of patients with diagnosed AB secondary to SARS-CoV-2. We performed a cross-sectional study of patients with AB and SARS-CoV-2 infection enrolled in the Prospective Epidemiological Study of COVID-19 in Children of the Spanish Pediatric Association (EPICO-AEP), from March 1, 2020 to February 28, 2021 . EPICO-AEP is a multicenter nationwide study aiming to describe COVID-19 in Spanish children. 13 A representative sample of 10% of all hospitals in Spain recruited patients, including all major pediatric hospitals in each Spanish region. All affiliated pediatricians received an email invitation to participate in the project from the Spanish Pediatric Association. All centers showing interest were included in the project. No facilities were excluded. Children younger than 18 years of age infected with SARS-CoV-2 who received care at any of the 80 participating hospitals were included in this registry. For the present analysis, the inclusion criteria were (i) children under 2 years of age with AB admitted to the hospital and (ii) positive reverse-transcriptase polymerase chain reaction (RT-PCR) assay for SARS-CoV-2 performed using nasopharyngeal swab/aspirate. In accordance with the classical criteria by McConnochie et al., AB was defined as the first episode of acute wheezing in children aged less than 2 years, beginning as a viral upper respiratory infection (coryza, cough, or fever). 14 Patients with previous episodes of wheezing were excluded. Confirmed infection was defined as the detection of SARS-CoV-2 nucleic acid by RT-PCR. The reported sensitivity of RT-PCR for the envelope (E)-gene and RNA-dependent RNA polymerase (RdRp) gene assays is 5.2 and 3.8 copies per reaction at 95% detection probability, respectively. 15 Both genes needed to be amplified in RT-PCR to report a positive result. RT-PCR for SARS-CoV-2 was performed on the premises of each participating center. Study data were standardized and prospectively collected by researchers from each center, entering the data into an encoded, confidential, unique online database using REDCap electronic data capture tools (Biomed Inform, 2009 ). 16 Data collected included clinical and sociodemographic variables. Continuous variables, ranges, interquartile ranges (IQR), and medians were presented in the case of nonnormally distributed variables and means and standard deviations when variables were normally distributed. Unless specified otherwise, the denominator for each percentage was the number of subjects within the population group, without considering missing observations. Data were analyzed using SPSS software 20.0 (IBM Corp.). By the end of February 2021, 666 children infected with SARS-CoV-2 who required hospital admission had been included in the registry, and 306 of them had a respiratory illness (45.9%). The most common diagnoses of admitted patients are reflected in Figure 1 . Thirteen patients were infants diagnosed as having AB. One patient was excluded as they did not meet the diagnostic criteria for AB. A total of 12 patients were included, representing 1.8% of admissions throughout the first year of the pandemic. Eight cases were admitted during the first wave of the pandemic, which lasted from March 2020 to May 2020 ( Figure 2 ). The epidemiological and clinical characteristics of these infants are summarized in Table 1 . The median age at presentation of AB was 1.9 months (range: 0.4-10.1 months). Six out of 12 were below 8 weeks of age. Six cases had household contact with confirmed or probable COVID-19 cases. None had underlying medical disorders. In all cases, RT-PCR for SARS-CoV-2 using nasopharyngeal swabs or aspirates detected viral nucleic acid on admission in the first sample. The most frequent complaints were cough (11 patients), rhinorrhea, 10 and work of breathing. 8 Eight presented fever on admission and one developed fever during admission. Median temperature in the emergency department (ED) was 37.6°C (range: 36.1-38.5°C); none presented fever >39°C during the course of the disease. The median time of fever before hospital admission was 2 days (range: 0-6 days) and none of them presented fever lasting more than 6 days (median: 2 days; range: 1-6 days). Gastrointestinal symptoms were infrequent (one case of diarrhea and one with vomiting), and none presented skin lesions. At admission, median percutaneous oxygen saturation in room air was 97% (range: 93%-100%) and respiratory rate was 49 rpm (range: 28-70 rpm) . According to the AB scoring system used in each center, six cases were classified as mild, five as moderate, and one as severe. The reason for admission in patients with mild AB was F I G U R E 1 SARS-CoV-2 hospital admissions due to a respiratory illness. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 F I G U R E 2 SARS-CoV-2 hospital admissions due to a respiratory illness by month. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 Although SARS-CoV-2 infection may be associated with AB in the absence of a viral coinfection, SARS-CoV-2 AB has not been a frequent cause of admission during the first year of the COVID-19 pandemic in Spain, one of the European countries most severely affected by the disease. 11, 12 These findings are similar to those described during the pre-COVID-19 era in which HCoVs were an infrequent cause of single-infection AB. 5, 6 When admitted, patients with SARS-CoV-2 AB did not have a more severe disease course. In our series of patients with AB, hospital admission was mostly motivated by patient age below 8 weeks. Young age is a known risk factor for severe disease in AB caused by other viruses. 15, 16 Therefore, local protocols usually recommend hospital admission for young infants with AB regardless of severity. Moreover, in the early stages of the pandemic, a more conservative approach regarding age was to be expected by attending pediatricians in the ED. According to clinical practice guidelines, clinicians should diagnose AB and assess disease severity based on history and physical examination; radiographic or laboratory studies should not be obtained routinely. 17, 18 An investigation by Parikh et al. showed that blood testing was ordered in 29% and CXR in 52% of patients admitted due to AB. 19 In our series, laboratory studies were ordered in 7/12 patients, likely due to concerns surrounding this emerging pathogen, though no remarkable results were found. On the other hand, a CXR was ordered in 6/12 cases despite a nonsevere course in most cases, and remarkable findings were found only in the patient coinfected with hMPV who required MV. Nowadays, pharmacological treatments should not be administered to infants and children with a diagnosis of AB. 17, 18 Nevertheless, it continues to be commonplace for hospitalized patients to receive bronchodilators (58%), antibiotics (33%), or steroids (16%) in the United States. 19 Similar figures of overuse of nonrecommended drugs have been reported in Spain. 20 In our series, bronchodilators were given to 4/12 patients. This low rate may reflect a cautious approach taken when considering nebulized treatments in the COVID-19 era due to the risk associated with these therapy approaches, but also due to the current strong evidence base advising against them. The nonsevere course of most cases of SARS-CoV-2 AB is reflected by the degree of supplemental oxygen needed during admission. Five patients did not require any oxygen at all, and in another six cases an ordinary nasal cannula was sufficient. Only the patient coinfected with hMVP required HFNC, CPAP, and MV. PICU admission was indicated in this unique patient, which is consistent with other series in which approximately 6%-17% of hospitalized children with AB required intensive care. 21, 22 Although the patient with the worst clinical evolution had a viral coinfection, most of the infants tested showed no presence of coinfection. Therefore, our study cannot contribute data on the behavior of this emerging virus in coinfection with other pathogens. According to recent studies, hMPV is one of the five most common pathogens in severe AB, accounting for 6% of the cases in the United States and in half of them acting as a single infection. 22 It is difficult to determine whether the hMPV itself or the combination of the two infections was responsible for the severity in the single case requiring MV in the series. On the one hand, endemic coronavirus coinfection, mainly with RSV, has not been associated with increased disease severity. 7 On the other hand, hMPV, either alone or in coinfection with RSV, is a known trigger of severe AB. 22, 23 Therefore Apart from the fact that SARS-CoV-2 does not seem to be a major trigger of AB, lockdown orders, physical distancing, maskwearing, and other nonpharmaceutical interventions do not only impact COVID-19 but also the dynamics of various other infectious diseases. 24, 25 Since the beginning of the pandemic, AB has been almost entirely absent due to the nonexistence of the 2020 winter RSV infection peak, first in the southern hemisphere 26, 27 and then in the northern hemisphere. 28, 29 Supporting this trend, the eight patients who were screened for RSV in our series were negative. Due to the nonexistence of RSV infection peaks, PICU admissions due to AB during the COVID-19 pandemic have been reduced dramatically. 30 As with other well-known viruses causing AB, neonatal apnea has been described as the presenting symptom of SARS-CoV-2 infection in a 16-day-old newborn who required PICU admission and nasal CPAP. 31 Finally, since the first year of the pandemic did not coincide with the RSV season, the behavior of this emerging virus in coinfection with this well-known trigger of AB is uncertain. In conclusion, single SARS-CoV-2 infection does not seem to be a main trigger of severe AB in children, and individuals with this condition should be managed according to clinical practice guidelines for AB. Project PI20/00095, from the Instituto de Salud Carlos III (Ministry of Economy, Industry and Competitiveness) and cofounded by the European Regional Development Fund. Elena Cobos is supported by a specific Research Project of the Spanish Society of Paediatrics Teresa del Rosal Elisa Fernández Fernando Cabañas Mª Inmaculada Olmedo, Agustín López, María Jose Pérez (Hospital Universitario Puerta de Hierro) Adriana Navas (Hospital Universitario Infanta Leonor) M. Luz García (Hospital de Leganés) María José Hernández (Hospital Central de la Defensa Ana López, Nerea Gallego María Méndez (Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol), Ángela Hurtado (Instituto Hispalense de Pediatría) Hospital La Moraleja), Isabel Romero Montesinos (Consorci Hospital General Universitari de València) Neus Rius, Alba Gómez Ana Campos (Hospital Universitario Sanitas La Zarzuela), Mercedes García (Hospital de Mérida) Mª Ángeles Vázquez, Miguel Sánchez Yeray Novoa Hospital General Universitari de Castelló) José María Olmos Raúl González (Hospital Sant Joan d'Alacant), Miguel Lafuente, Matilde Bustillo (Hospital Infantil de Zaragoza) Morata (Hospital Lluís Alcanyis) Nerea Domínguez-Pinilla Leonor García Maset (Hospital de Sagunto) Elena Cobos-Carrascosa: Data curation (supporting); investigation (supporting); project administration (supporting); writing review & editing (supporting). Inmaculada Bodegas: Investigation (supporting) Cinta Moraleda: Data curation (equal); investigation (equal); project administration (equal); writing review & editing (supporting). Alfredo Tagarro: Data curation (equal); investigation (equal) writing review & editing (supporting) DATA AVAILABILITY STATEMENT REFERENCES Epidemiology and clinical features of human coronaviruses in the pediatric population SARS-CoV-2 infection in children Children hospitalized for coronavirus disease 2019 (COVID-19): a multicenter retrospective descriptive study Recent trends in severe respiratory syncytial virus (RSV) among US infants Viral etiologies of infant bronchiolitis, croup and upper respiratory illness during 4 consecutive years Severe coronavirus bronchiolitis in the pre-COVID-19 era Delayed acute bronchiolitis in infants hospitalized for COVID-19 Low impact of SARS-CoV-2 infection among paediatric acute respiratory disease hospitalizations Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections European Center for Disease Prevention and Control. COVID-19 situation update worldwide, as of 1 Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid What's in the name? Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis Australasian bronchiolitis guideline Bronchiolitis management before and after the AAP guidelines Research Group of the aBRE-VIADo Project. Overuse of bronchodilators and steroids in bronchiolitis of different severity: bronchiolitis-study of variability, appropriateness, and adequacy Trends in bronchiolitis hospitalizations in the United States Respiratory virus epidemiology among US infants with severe bronchiolitis: analysis of 2 multicenter, multiyear cohort studies Impact of human metapneumovirus and respiratory syncytial virus co-infection in severe bronchiolitis Pediatric hospitalizations during the COVID-19 pandemic Coronavirus disease 2019 pandemic: impact caused by school closure and national lockdown on pediatric visits and admissions for viral and nonviral infections-a time series analysis Early impact of social distancing in response to coronavirus disease 2019 on hospitalizations for acute bronchiolitis in infants in Brazil Impact of coronavirus disease 2019 public health measures on detections of influenza and respiratory syncytial virus in children during the 2020 Australian winter Bronchiolitis in COVID-19 times: a nearly absent disease? Infant bronchiolitis dramatically reduced during the second French COVID-19 outbreak Bronchiolitis admissions to intensive care during COVID Can SARS-CoV-2 cause life-threatening bronchiolitis in infants? SARS-CoV-2 acute bronchiolitis in hospitalized children: neither frequent nor more severe Data available on request due to privacy/ethical restrictions. http://orcid.org/0000-0002-3082-8832